Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab

医学 无容量 内科学 肿瘤科 头颈部癌 头颈部鳞状细胞癌 无进展生存期 接收机工作特性 癌症 临床终点 免疫组织化学 对数秩检验 PD-L1 生存分析 胃肠病学 总体生存率 免疫疗法 临床试验
作者
Isaku Okamoto,Hiroki Sato,Kiyoaki Tsukahara
出处
期刊:Auris Nasus Larynx [Elsevier BV]
卷期号:47 (4): 676-686 被引量:13
标识
DOI:10.1016/j.anl.2020.04.001
摘要

Objective Our facility measures programmed cell death ligand 1 (PD-L1) expression in all patients before administering nivolumab. The aim of the present study is to clarify the association between overall survival (OS) and PD-L1 expression. Patients and Methods Subjects in this study were 52 patients with R/M-HNC cancer (45 men, 7 women) administered nivolumab in our facility between June 1, 2017 and January 31, 2019. Mean age was 62.2 years (median, 65 years; range, 28–81 years). Histopathological type was squamous cell carcinoma (SCC) in 48 cases, and non-SCC in 4 cases. We set OS as the primary endpoint and progression-free survival (PFS), overall response rate (ORR), association of OS and PD-L1 expression and association of PFS and PD-L1 expression as secondary endpoints. The cut-off for PD-L1 expression was set using the receiver operating characteristic (ROC) curve. We compared OS, PES and ORR using this PD-L1 cut-off for all patients and for the SCC group. OS and PFS were calculated using Kaplan-Meier methods. The log-rank test was used for statistical analysis, with values of p < 0.05 taken as significant. For PD-L1 immunohistochemistry assays, Dako 28-8 antibody was used. Results In the all-patients group, median OS was 9.6 months and 1-year OS rate was 40.4%. Median PFS was 4.0 months and 1-year PFS rate was 37.8%. The cut-off value of PD-L1 expression for OS was 40% for all patients and the SCC group. When PD-L1 expression was ≥40%, OS was significantly better in both all patients and the SCC group (p = 0.004, 0.007). The cut-off value of PD-L1 expression for PFS was also 40%. When PD-L1 expression was ≥40%, PFS was better in all patients and the SCC group (P = 0.003, 0.009). In the all-patients group, ORR was 19.2% and disease control rate (DCR) was 44.2%. When PD-L1 expression was ≥40%, ORR was 44.4% and DCR 83.3%. Conclusion In the present study, when PD-L1 expression was high (≥40%), OS was significantly better (p = 0.004). This finding has not been reported in other research on R/M-HNC. PFS and ORR were also better with high PD-L1 expression. Regarding patterns of progression with a PD-L1 expression cut-off of 40%, hyperprogression was significantly more frequent for PD-L1 expression <40% (p = 0.039). Therefore, high PD-L1 expression could offer a predictor of prognosis and efficacy for nivolumab. The present findings may prove useful in considering treatment strategies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
奶油泡fu完成签到 ,获得积分10
2秒前
dong东包完成签到,获得积分20
3秒前
3秒前
ED应助cccccc采纳,获得10
3秒前
shangziru发布了新的文献求助10
4秒前
漠之梦完成签到,获得积分20
5秒前
sc完成签到,获得积分10
5秒前
谦让的含海完成签到,获得积分10
5秒前
好运連連完成签到,获得积分10
6秒前
8秒前
liu完成签到,获得积分10
8秒前
飞翔的霸天哥应助Yuanchaoyi采纳,获得30
9秒前
香蕉觅云应助WJH采纳,获得10
10秒前
汉堡包应助研友_LOoomL采纳,获得10
10秒前
小二郎应助Felix采纳,获得10
10秒前
zaphkiel完成签到 ,获得积分10
11秒前
健壮的囧完成签到,获得积分10
12秒前
torch132完成签到,获得积分10
13秒前
桐桐应助阿景采纳,获得10
14秒前
14秒前
震动的平松完成签到 ,获得积分10
14秒前
Ting完成签到 ,获得积分10
15秒前
15秒前
Hello应助王冉冉采纳,获得30
16秒前
Ava应助Jarvi采纳,获得10
16秒前
17秒前
18秒前
19秒前
一枚研究僧完成签到,获得积分0
19秒前
19秒前
赘婿应助科研通管家采纳,获得10
20秒前
英姑应助科研通管家采纳,获得10
20秒前
思源应助科研通管家采纳,获得10
20秒前
上官若男应助科研通管家采纳,获得10
20秒前
Jasper应助科研通管家采纳,获得10
20秒前
1351567822应助科研通管家采纳,获得30
20秒前
领导范儿应助科研通管家采纳,获得10
20秒前
合适的毛豆完成签到,获得积分10
21秒前
深情安青应助科研通管家采纳,获得10
21秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038569
求助须知:如何正确求助?哪些是违规求助? 3576279
关于积分的说明 11374944
捐赠科研通 3305979
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815048